Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Increased by Man Group plc

Man Group plc increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 24.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 315,817 shares of the biopharmaceutical company’s stock after buying an additional 61,123 shares during the quarter. Man Group plc’s holdings in Catalyst Pharmaceuticals were worth $6,591,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Summit Investment Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 580 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Catalyst Pharmaceuticals by 6.2% during the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 875 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock worth $6,518,000 after acquiring an additional 952 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after acquiring an additional 1,000 shares in the last quarter. Finally, PDT Partners LLC raised its holdings in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 1,030 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 351,879 shares of company stock worth $8,214,815. Company insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $24.63 on Tuesday. The business’s 50-day simple moving average is $23.30 and its 200-day simple moving average is $22.50. The firm has a market capitalization of $3.00 billion, a PE ratio of 20.87, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.16.

Analyst Ratings Changes

Several brokerages recently issued reports on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.